VICTR
-
November 10, 2022
Clinical trial at VUMC tests novel treatment for asthma
VUMC has begun enrolling patients with asthma in a clinical trial of a novel treatment: a medication approved to treat diabetes and obesity. -
October 6, 2022
VUMC to test whether Alzheimer’s drug can ease lupus symptoms
Vanderbilt University Medical Center is partnering with Evergreen Therapeutics Inc. to test whether an Alzheimer’s drug, memantine, can improve cognitive symptoms associated with systemic lupus. -
September 22, 2022
Self named co-principal investigator of Vanderbilt’s Clinical and Translational Science Award
Wesley Self, MD, MPH, a physician-scientist at Vanderbilt University Medical Center, has been named co-principal investigator (co-PI) of Vanderbilt’s Clinical and Translational Science Award (CTSA). -
August 17, 2022
Researchers discover how salt increases blood pressure
A Vanderbilt research team has discovered that activation of a certain protein complex involved in the inflammatory response in immune cells contributes to salt-sensitive hypertension. -
June 16, 2022
Researchers add sign language videos to electronic surveys
A new external module in Vanderbilt's REDCap improves electronic survey accessibility for respondents who are deaf. The module makes it easy to embed individual sign language videos for each survey question and answer. -
April 6, 2022
Major grant renewal to provide five more years of support for VICTR
Vanderbilt University Medical Center has competed successfully for a third renewal of its Clinical and Translational Science Award by the National Institutes of Health. -
May 6, 2021
VUMC to lead national study to treat severe COVID complications
The Vanderbilt Institute for Clinical and Translational Research (VICTR) has been awarded a major federal grant to lead a national trial of treatments targeting the Renin Angiotensin Aldosterone System (RAAS) in patients hospitalized with COVID-19.